Friday, 5 June 2020

FDA - Q3D(R1) Elemental Impurities



FDA has now published this final guidance. Elemental impurities in drug products may arise from several sources; they may be residual catalysts that were added intentionally in synthesis or may be present as impurities (e.g., through interactions with processing equipment or container/closure systems or by being present in components of the drug product). Because elemental impurities do not provide any therapeutic benefit to the patient, their levels in the drug product should be controlled within acceptable limits.




Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Thursday, 4 June 2020

Communities of microbes found to have working memory



Biologists studying communities of bacteria have discovered that these so-called simple organisms feature a robust capacity for memory. Using light, researchers were able to encode complex memory patterns and visualize cells with memory. The discovery reveals surprising parallels between low-level single-celled organisms and sophisticated neurons that process memory in the human brain. The finding also provides a starting path for scientists to one day design basic computing systems with living organisms such as bacteria.

Following recent discoveries by the Süel lab that bacteria use ion channels to communicate with each other, new research suggested that bacteria might also have the ability to store information about their past states. In the new study, the researchers were able to encode complex memory patterns in bacterial biofilms with light-induced changes in the cell membrane potential of Bacillus subtilis bacteria. The optical imprints, they found, lasted for hours after the initial stimulus, leading to a direct, controllable single-cell resolution depiction of memory.


The ability to encode memory in bacterial communities, the researchers say, could enable future biological computation through the imprinting of complex spatial memory patterns in biofilms.

See:

Chih-Yu Yang, Maja Bialecka-Fornal, Colleen Weatherwax, Joseph W. Larkin, Arthur Prindle, Jintao Liu, Jordi Garcia-Ojalvo, Gürol M. Süel. Encoding Membrane-Potential-Based Memory within a Microbial Community. Cell Systems, 2020; DOI: 10.1016/j.cels.2020.04.002

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Wednesday, 3 June 2020

FDA - Safety testing of drug metabolites



This guidance provides recommendations to industry on when and how to identify and characterize drug metabolites whose nonclinical toxicity needs to be evaluated. Drug metabolites may need to be determined in nonclinical studies when they are disproportionate drug metabolites, that is, metabolites identified only in humans or present at higher plasma concentrations in humans than in any of the animal species used during standard nonclinical toxicology testing.
See: https://www.fda.gov/media/72279/download

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Tuesday, 2 June 2020

New insight into bacterial structure to help fight against superbugs



Scientists have produced the first high-resolution images of the structure of the cell wall of bacteria, in a study that could further understanding of antimicrobial resistance.

The findings set a new framework for understanding how bacteria grow and how antibiotics work, overturning previous theories about the structure of the outer bacterial layers.

The images give unprecedented insight into the composition of the bacterial cell wall and will inform new approaches to developing antibiotics in order to combat antibiotic resistance. There are no other examples of studies of the cell wall in any organism at comparable resolution, down to the molecular scale.


The team used an advanced microscopy technique called Atomic Force Microscopy (AFM), which works by using a sharp needle to feel the shape of a surface and build an image similar to a contour map, but at the scale of individual molecules.

See:

L. Pasquina-Lemonche, J. Burns, R. D. Turner, S. Kumar, R. Tank, N. Mullin, J. S. Wilson, B. Chakrabarti, P. A. Bullough, S. J. Foster, J. K. Hobbs. The architecture of the Gram-positive bacterial cell wall. Nature, 2020; DOI: 10.1038/s41586-020-2236-6 

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Monday, 1 June 2020

Technological developments with wound treatment dressings



Dressings are long-established in the medical field for keeping wounds clean and preventing secondary infections. Dressings are essential for reducing infection risk; more recent advancements have seen dressings developed to promote wound healing.

In relation to this, Tim Sandle has written an article for Infectious Disease Hub. Here is an extract:

Wound healing refers to a specific biological process related to the general phenomenon of growth and tissue regeneration. Wounds heal by the control of moisture and by a process of staving off infection; while dressings have addressed the former over centuries, with the latter specialized dressings are being developed. Dressings to aid wound healing have been used for several decades, such as the use of hydrocolloid dressings to help treat burns and with the application of hydrogels for wounds that are leaking little or no fluid. However, it is in more recent years that antimicrobial compounds have been incorporated.

This involves the addition of physical or chemical processes designed to kill any pathogenic microorganisms that might be present, and which pose a risk of triggering a disease such as sepsis (where the chemicals that body’s immune system releases into the bloodstream to combat an infection trigger inflammation throughout the entire body) or delay the rate of wound healing (one of the causes of delayed wound healing is the presence of microorganisms in the wound). This article examines some of these developments, and also considers an additional development in the form of color-changing dressings for signaling the presence of antimicrobial-resistant bacteria.


The article can be accessed here.

The reference is:

Sandle, T. (2020) Technological advances with dressings for wound treatment and detection, Infectious Disease Hub, published on 19th February 2020. At: https://www.id-hub.com/2020/02/20/technological-advances-with-dressings-for-wound-treatment-and-detection/

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Saturday, 30 May 2020

Plastic eating bacterium offers pollution hope



German scientists have found a small solution to this big problem – plastic-eating bacteria.
This newly identified strain of Pseudomonas bacteria was discovered by a team consisting of researchers from Helmholtz Centre for Environmental Research (Leipzig, Germany), Freiberg University of Mining and Technology (Germany) and Helmholtz Centre for Infection Research (Braunschweig, Germany), who have demonstrated its ability to break down polyurethane, a toxic type of plastic that is particularly hard to recycle.

In 2015 alone, polyurethane accounted for 3.5 million tons of the plastic produced in Europe. Its lightweight, insulating and flexible properties make it suitable for use in many products, from shoes and refrigerators to kitchen sponges. However, it’s incredibly difficult and energy-intensive to recycle, so most ends up on landfill sites where it releases toxic, often carcinogenic, chemicals.

Most bacteria are unable to withstand the toxic fumes released by the plastic, but, as demonstrated in a recent study published in Frontiers in Microbiology, this newly discovered strain is able to not only withstand and survive in the harsh environment, but also degrade some of the chemical building blocks of polyurethane and use these for energy.

For further details, see Biotechniques: https://www.biotechniques.com/microbiology-virology/a-tiny-solution-for-plastic-pollution-scientists-discover-polyurethane-feeding-bacteria  

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Monday, 18 May 2020

Ready for The Count? Back-To-Basics Review Of Microbial Colony Counting


Microbiological laboratories remain reliant on the accurate determination of the number of colony forming units (CFUs) on growth media; this is notwithstanding advances with rapid microbiological methods, at least for some applications. Mainstay methods include pour plates, spread plates, and membrane filtration. Counting of microbes is important as it enables a laboratory to estimate the microbial population in a variety of products (bioburden). Yet there are limitations with plate count methods, including the fact that they only count viable cells and culturable organisms.


Tim Sandle looks at the issue of colony counting from a new perspective, including limitations with the human eye, and with how data integrity can be improved.

The reference is:

Sandle, T. (2020) Ready for The Count? Back-To-Basics Review Of Microbial Colony Counting, Journal of GxP Compliance, 24 (1) : http://www.ivtnetwork.com/article/ready-count-back-basics-review-microbial-colony-counting

For details, please contact Tim Sandle

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Thursday, 14 May 2020

What type of cells does the novel coronavirus attack?


Scientists from the Berlin Institute of Health (BIH), Charité -- Universitätsmedizin Berlin and the Thorax Clinic at Heidelberg University Hospital, whose collaboration is taking place under the auspices of the German Center for Lung Research (DZL), have examined samples from non-virus infected patients to determine which cells of the lungs and bronchi are targets for novel coronavirus (SARS-CoV-2) infection. They discovered that the receptor for this coronavirus is abundantly expressed in certain progenitor cells. These cells normally develop into respiratory tract cells lined with hair-like projections called cilia that sweep mucus and bacteria out of the lungs.

The scientists knew, from studies by BIH Professor Christian Drosten, director of the Institute of Virology at Campus Charité; Mitte, and by others, that the virus's spike protein attaches to an ACE2 receptor on the cell surface. In addition, the virus needs one or more cofactors for it to be able to penetrate cells. But which cells are endowed with such receptors and cofactors? Which cells in which part of the respiratory system are particularly susceptible to SARS-CoV-2 infection? Eils and his colleagues at the BIH and Charité; now used single-cell sequencing technology to examine the cells in the samples from Heidelberg.
60,000 single cells were sequenced


The researchers discovered that certain progenitor cells in the bronchi are mainly responsible for producing the coronavirus receptors. These progenitor cells normally develop into respiratory tract cells lined with hair-like projections called cilia that sweep mucus and bacteria out of the lungs.

See:

Soeren Lukassen, Robert Lorenz Chua, Timo Trefzer, Nicolas C. Kahn, Marc A. Schneider, Thomas Muley, Hauke Winter, Michael Meister, Carmen Veith, Agnes W. Boots, Bianca P. Hennig, Michael Kreuter, Christian Conrad & Roland Eils. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. EMBO Journal, 2020 DOI: 10.15252/embj.20105114

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Friday, 8 May 2020

Nosopharm develops a first-in-class novel antibiotic



Nosopharm, specialized in exploring unconventional sources of antibiotics to discover new drugs to fight antimicrobial resistance, today announces it has been granted a US patent for NOSO-502. NOSO-502 is Nosopharm’s first clinical candidate in a new class of antibiotics called Odilhorhabdins, aimed at eradicating resistant bacteria. This patent secures Nosopharm’s market exclusivity rights in the US, the leading pharmaceutical market. It also covers numerous chemical analogs - the chemical space of NOSO-502 – thereby reinforcing its protection against exploitation by competitors.

Besides the US patent (US Patent No. 10,626,144), Nosopharm has been granted a patent in Russia, and a notice of acceptance has recently been issued in Australia. In addition, the company has filed patent applications in Canada, China, Europe (EPO), Japan, Hong Kong, Brazil, South Korea, India, Israel and Mexico. Apart from Canada and South Korea, which start examining patent applications later than other countries, decisions are pending in all these territories and are expected to be announced during the course of this year.

“The award of a US patent for our clinical candidate NOSO-502 is a key milestone in Nosopharm’s development,” said Philippe Villain-Guillot, co-founder and chief executive officer at Nosopharm. “The US market is the global leader in pharmaceuticals and we have now secured exclusive marketing rights there. Backed by this IP, there is significantly more incentive for both a potential industrial partner to in-license the NOSO-502 program and further developments to combat resistant bacteria.”

The growing resistance of pathogenic bacteria is a threat to the efficacy of antibiotics. In 2015 antibiotic-resistant bacteria were estimated to be responsible for 670,000 infections and 33,110 attributable deaths in the EU and the European Economic Area (EEA). From a global perspective, antimicrobial resistance could kill up to ten million people every year by 2050, which could cost up to €94 trillion ($100tn).

Nosopharm investigates a new class of antibiotics, Odilhorhabdins, that inhibit the bacterial ribosome with a new mechanism of action. It is intended for treating nosocomial infections caused by Enterobacteriaceae, including polymyxin– and carbapenem-resistant Enterobacteriaceae (CRE). In 2017, the WHO published a list of priority pathogens for the development of new antibiotics. Carbapenem-resistant Gram-negative bacteria (Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter baumannii) were at the top of that list, with critical priority.



NOSO-502 has proven to be effective in vivo in Enterobacteriaceae infection models and demonstrated antibacterial activity in vitro against multi-drug resistant clinical isolates (KPC, NDM and OXA among others).

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Saturday, 2 May 2020

Coronavirus testing, antivirals, vaccines and other measures



Posted by Dr. Tim Sandle,
Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Sunday, 19 April 2020

EU GMP Annex 21


Annex 21 to the EU-GMP Guidelines has been published as a draft (on 20th March 2020), titled "Importation of medicinal Products".

The Annex is aimed at Manufacturing and Importation Authorisation holders (MIA holders) who import human or veterinary medicinal products from third countries.
The Annex does not cover products that do not have a marketing authorisation in the EU/EEA and are directly re-exported.

The Annex includes:

·         Physical transfer from the third country to the EU/EEA
·         Certification by the Qualified Person (QP) (link with the requirements of Annex 16)
·         Requirements for equipment and facilities
·         Required documentation

·         GMP requirements for manufacturers and exporters in third countries
·         Qualification and audits under the responsibility of the importing company and the Qualified Person (QP)
·         Import testing
·         Contractual regulations between all companies or persons involved in the import

For details, see: https://ec.europa.eu/health/sites/health/files/files/gmp/importation_medicinalproducts_draftannex21_en.pdf

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Saturday, 11 April 2020

Knowing more about a virus threat may not satisfy you


People who rate themselves as highly knowledgeable about a new infectious disease threat could also be more likely to believe they don't know enough, a new study suggests.
In the case of this study, the infectious disease threat was the Zika virus. But the authors of the new study, published recently in the journal Risk Analysis, say the results could apply to the recent novel coronavirus (COVID-19) outbreak.

"The Zika virus and the coronavirus have important things in common," said Shelly Hovick, co-author of the study and assistant professor of communication at The Ohio State University.
"In both cases, they are shrouded in uncertainty and have received a lot of media attention. Our research looks at how people seek and process information when there is so much uncertainty."

One of the key findings of the new study: With limited information about Zika available, more knowledge was not that comforting.

"We found that the more people thought they knew, the more they realized they didn't know enough," said Austin Hubner, lead author of the study and a doctoral student in communication at Ohio State.


"With the Zika virus, even the experts themselves didn't know much at the time. That's the same thing we're seeing with the coronavirus, and that's scary for people who believe they are at risk."

For the study, the researchers conducted an online survey of 494 people of childbearing age living in Florida in December 2016.

See:

Austin Y. Hubner, Shelly R. Hovick. Understanding Risk Information Seeking and Processing during an Infectious Disease Outbreak: The Case of Zika Virus. Risk Analysis, 2020; DOI: 10.1111/risa.13456

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Monday, 30 March 2020

Guide to sterility test isolators


An isolator is an arrangement of physical barriers that are integrated so that the workspace (an enclosed environment) within the isolator is sealed from the outside environment. Isolators provide a testing environment free from contamination, through routine sanitization using a validated cycle and confirmed by environmental monitoring.

In addition, these devices enable the isolation between the operator and the process. There are many complications with isolators, from design to qualification, and with general operation.

It certainly remains that isolators cannot prevent contamination caused by GMP deficiencies such as poor aseptic procedures and inadequate training of operators.

To address these concerns and to outline best practices, Tim Sandle has written a new Pharmig guide:

Sandle, T. (2019) Guide to sterility test isolators, Pharmig, Stanstead Abbotts: UK (ISBN 978-0-9560804-9-3)

Foe details see: https://www.pharmig.org.uk/en/products/publications/

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Saturday, 1 February 2020

Antimicrobial resistance bacteria found in raw pet food


The fight against antimicrobial resistance has a new problem – raw pet food, according to new research. Sales of biologically appropriate raw food, especially for dogs, have risen in recent years.

Microbiologists working in Switzerland have assessed 51 samples of raw diet pet food, drawn from different suppliers in stores as well as from the Internet. The analysis revealed that some three-quarters of the food samples contained bacteria that has the potential to trigger gastrointestinal infections limits.

Furthermore, over half of the foods that tested were found to contai bacteria that are resistant to antimicrobials, meaning that such organisms are hard to kill. Among the bacteria were certain strains of Escherichia coli. Some bacteria can produce the enzyme extended-spectrum beta-lactamase (EBSL), which can enable these microorganisms to resist the impacts of antibiotics.

Other pathogens that have been isolated from raw pet food includes Campylobacter spp, Clostridium spp, enterotoxigenic Staphylococcus aureus, Listeria monocytogenes, and Salmonella spp.

According to lead researcher Dr. Magdalena Nuesch-Inderbinen: “It is really worrying that we found EBSL-producing bacteria in over 60 percent of samples.”

The new research highlights a new area of concern in the battle against antimicrobial resistance. Antimicrobial resistance is a phenomenon the occurs naturally as bacteria respond to various pressures within the environment. What is of concern is the worldwide acceleration of resistance. U.S. Centers for Disease Control and Prevention (CDC) data finds that many high-income countries are entering a “post antibiotic era.”


One reason for the trend is linked to the practice of animal feed-additive antibiotic usage, which is some countries is an integral part of animal-production technology. The reason for adding of antibiotics is for the creation of 'leaner' meat (animals given antimicrobial tend to grow more quickly). In addition, the indiscriminate administering of antibmicrobials to animals is a way of side-stepping putting in place better animal hygiene conditions.  Many countries have banned this practice, but it also continues in many other parts of the world.

The study additionally highlights concerns for pet owners when considering to buy raw food and then how that food is handled in the home.  In fact, the American Veterinary Animal association “discourages the feeding to cats and dogs of any animal-source protein that has not first been subjected to a process to eliminate pathogens because of the risk of illness to cats and dogs as well as humans.”

The research findings have been reported in the journal Royal Society Open Science.

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology

Monday, 27 January 2020

Integrating Good Distribution Practice into the QMS

Good Distribution Practice (GDP) concerns the distribution processes for pharmaceutical products that results in medics and patients obtaining access to the medications required. For the pharmaceutical organization, the distribution process occurs both upstream and downstream. Upstream are the suppliers who create goods and services used in a manufacturer’s own operations, such as raw components or materials. The downstream supply chain efficiently distributes a company’s products or services to its customers. Each stage, both upstream and downstream, needs to be proactively managed to minimize quality, as well as financial, confidentiality, operational, reputational and legal risks.


Here is an extract:

These distribution processes concern supply chain, including cold supply chains (where required), and the tracking and tracing of medicines. Traceability includes ensuring that the required environmental controls are met, and that tampering or fraudulent activities are avoided, to the level that each induvial item can be traced from the completion of manufacture to its arrival with the end user (Marucheck et al, 2011). The distribution network for medicinal products is invariably complex and it involves many different parties at different stages. In addition to the challenges associated with this complexity and with protecting the product from being affected by environmental conditions, damage, or loss, there is also a threat from criminal activities centered on seeking to introduce falsified medicines into the supply chain (Bruinsma, and Bernasco, 2004).

GDP requirements are designed to codify and to structure the processes. These requirements bear close similarity to the requirements set out in Good Manufacturing Practice (GMP) regulations. The primary difference is that GDP covers the wholesale distribution of medicines, whereas GMP covers their manufacture.  There overlap between the two rest with the need to maintain product quality after a batch has been released from the manufacturing site, as well as the necessity to monitor and control complaints, address problems, and have a system in place to enact a recall.

In assessing the requirements for GDP, there are different national and supranational standards. In the US GMP is based on the Code of Federal Regulations 21 CFR 210/211, with additional guidance contained within USP chapter 1079 “Good Storage and Distribution Practices for Drug Products.” (USP, 2018) There is an additional USP chapter of interest, chapter 1197 “Good Distribution Practices for Pharmaceutical Excipients” (USP, 2018b). For Europe GDP is based on the Directive of the Board of the European Community 92/25/EEC regarding the wholesale distribution of drugs for human consumption, supported by guideline 2015/C 95/01 (European Commission, 2015), and the Falsified Medicines Directive (European Commission, 2011), which requires a unique identifier and an anti-tampering device to allow the verification of the authenticity of medicinal products. With the World Health Organization, the applicable text is Annex 5 of the WHO recommendations “good distribution practices for pharmaceutical products.” (WHO, 2010a) One commonality through these regulations and following on from items raised during pharmaceutical organization inspections, is with a focus on serialization. This has required for new strategies, processes, and technologies that allow for a business to, at any time, pinpoint the location and origin of any single drug.


A weak GDP system is one where there is a key disconnect between the manufacturer and the process that occurs once the product leaves the facility (Rees, 2013). An overarching area of regulatory concern is with the effectiveness of the incorporation of GDP into the Quality Management System (QMS), a system that applies for both wholesaler and broker. This chapter looks at Quality Risk Management in relation to GDP, covering areas like good distribution principles, the necessity of having Quality Technical Agreements in place, and measures to take appropriate corrective and preventative actions should deviations occur.


The reference is:

Sandle, T. (2019) Integrating Good Distribution Practice into the QMS. In Schmitt, S. (Ed.) Good Distribution Practice: A Handbook for Healthcare Manufacturers and Suppliers, Volume 1, DHI/PDA Books, River Grove, IL, USA, pp241-272

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology

Special offers